Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.

When you think about sleep supplements, melatonin probably comes to mind first. It's undoubtedly the most popular sleep ...

Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Major discrepancies are seen with the use of noninvasive tests compared with liver biopsy in a posttransplant setting.

Hepatitis A and hepatitis E are viral infections that primarily affect the liver and are transmitted through the fecal-oral ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable endometrial cancer, according to findings presented at the SGO 2025 Annual ...

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report ...

Vistagen Therapeutics, Inc.’s VTGN share price has dipped by 10.10%, which has investors questioning if this is right time to buy.

Explore the best testosterone booster supplements in 2025 to help enhance energy, muscle growth, and hormonal balance ...